Cartesian Therapeutics, Inc. (RNAC) — Stock Score Summary

Cartesian Therapeutics, Inc. (RNAC) has a MoatMap StockRank of 17/100 based on Quality (25/100), Value (42/100), and Momentum (36/100) factor scores. The current signal is STRONG SELL. Cartesian Therapeutics is an early-stage cell therapy developer. While its RNA-based approach is scientifically interesting, it is highly speculative, capital-intensive, and lacks the commercial-stage cash flows we require.

Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company developing mRNA cell therapies for autoimmune diseases and cancer. The company utilizes its proprietary RNA cell therapy platform to create highly engineered, autologous cell therapies that avoid genetic modification and minimize manufacturing complexity. This innovative approach to cell therapy, particularly its focus on autoimmune indications, distinguishes Cartesian in the competitive biotechnology landscape by offering a potentially safer and more scalable therapeutic modality.

Key Financial Metrics

Price$6.85
Market Cap$212M
P/E (Forward)-2.44
Price/Book-1.26
Return on Invested Capital-30.8%
Gross Margin0.0%
Operating Margin-33973.1%
Revenue Growth-92.9%
Free Cash Flow$-47M

Cartesian Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Cartesian Therapeutics, Inc.’s (RNAC) StockRank?
MoatMap’s StockRank for Cartesian Therapeutics, Inc. (RNAC) is 17/100, with a Strong Sell signal. It is a composite of Quality (25), Value (42), and Momentum (36) factor ranks across MoatMap’s 19,000+ stock universe.
Does Cartesian Therapeutics, Inc. have an economic moat?
Cartesian Therapeutics, Inc. (RNAC) has a Quality factor score of 25/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Cartesian Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Cartesian Therapeutics, Inc. (RNAC) is Strong Sell, based on a StockRank of 17/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Cartesian Therapeutics, Inc. in?
Cartesian Therapeutics, Inc. (RNAC) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksRNAC deep dive reportAI ChampionsHow we score stocksSense-check another stock